Microsoft is expanding its use of AI to serve vertical industries with a Bristol Myers Squibb partnership that taps AI algorithms for early detection of lung cancer by radiologists.
The innovation being driven by Microsoft and the biopharmaceutical giant follows other healthcare AI initiatives we’ve analyzed including Duke Health governance strategies built on Microsoft infrastructure and an Avanade AI framework, as well as successful deployments of Microsoft Copilot technology in clinical settings. In late 2025, the company expanded its clinical Dragon for Copilot to support radiology use cases.
New Partnership Details
Microsoft and Bristol Myers Squibb are working to address a major health issue in the US: lung cancer is the cause of approximately 125,000 deaths and 227,000 new cases annually.
The partners are together tapping Food and Drug Administration-approved AI algorithms for radiology that are deployed in Microsoft’s Precision Imaging Network, which is a Microsoft Cloud for Healthcare Radiology Solutions. More than 80% of hospitals in the US utilize the imaging network to share medical imaging and access third-party imaging AI.
In total, the imaging network provides access to dozens of AI models for a range of exam types and body areas for early diagnosis and informed treatment. Specific to lung cancer, available AI capabilities can automatically analyze X-ray and CT images to help identify lung disease, supporting radiologists in their daily workflow and helping reduce clinical workload.
AI can help surface hard to detect lung nodules, identify patients at earlier stages of lung cancer, and help triage them for appropriate care.
“An integrated, AI-powered platform that streamlines patient flow can significantly improve operational efficiency and patient outcomes,” said Dr. Alexandra Goncalves, VP and Head of Digital Health, Bristol Myers Squibb.
Peter Durlach, Corporate Vice President and Chief Strategy Officer, Microsoft Health and Life Sciences, added, that with Microsoft’s AI radiology platform “clinicians can more easily identify patients who may be showing early signs of cancer—often before they are aware of any symptoms—and help guide them into the appropriate care pathway sooner.”
Microsoft and Bristol Myers Squibb noted that the partnership has a core objective to expand access to early detection in medically underserved communities such as rural hospitals and community clinics. Medically underserved populations experience higher lung cancer mortality rates and are less likely to receive screening in line with accepted guidelines.
With AI tools, they’re promoting earlier diagnosis and follow-up in these settings, and therefore more equitable care. Workflow management tools will track patients with lung nodules and help ensure regular follow-up.
Vertical Industry Inroads
Microsoft’s expansive approach to the use of AI in healthcare spans cancer detection all the way to streamlining clinical interactions between doctors and patients, reflecting the opportunity that AI presents to modernize and streamline healthcare from screening and testing to delivery of care.
The continuing emergence of AI-powered use cases is a powerful indicator of how AI is driving innovation in the form of new ways of operating in processes that are core to the healthcare field.
Coming on the heels of a big Microsoft retail AI push earlier this month, these developments bode well for AI’s emergence in 2026 as a powerful technology to deliver industry-specific outcomes and advances.
AI Agent & Copilot Summit is an AI-first event to define opportunities, impact, and outcomes with Microsoft Copilot and agents. Building on its 2025 success, the 2026 event takes place March 17-19 in San Diego. Get more details.
Tom Smith
Analyst
Cloud Wars, Agent and Copilot
Related Posts
